Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OQY-6129
- Development stage
- Unknown
- Lead developer
- Sorrento Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OQY-6129 (formerly DS-6129) is a first-in-class antibody-drug conjugate (ADC) targeting CD46, a protein often overexpressed in various hematologic and solid malignancies. Developed by Vivasor (Oqory, Inc.) and originally part of the Daiichi Sankyo pipeline, the drug consists of a monoclonal antibody against CD46 conjugated to a cytotoxic payload, typically a camptothecin derivative using the C-lock or DXD technology. It is currently being evaluated in Phase 1 clinical trials for the treatment of relapsed/refractory multiple myeloma and amyloidosis. Additionally, it has been associated with breakthrough therapy designation in Class 1c triple-negative breast cancer (TNBC) and is being studied in patients with all-drug-refractory solid tumors.
- Other names
- DS-6129/OQY-6129
02
Targets
CD46 (CD46 Molecule)
Beyond the preview
Go deeper on OQY-6129.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OQY-6129.